Management of Elderly Patients with Residual Prostate Cancer and Elevated PSA After Radical Prostatectomy

Initial Assessment and Risk Stratification

The American Urological Association recommends confirming biochemical recurrence using the standard definition: PSA ≥0.2 ng/mL with a second confirmatory level ≥0.2 ng/mL 1, 2
PSA should become undetectable (<0.2 ng/mL) within several weeks of surgery; any detectable or rising PSA indicates residual or recurrent disease 2

For patients with life expectancy >10 years, the British Journal of Cancer suggests pursuing curative salvage treatment 3, 4
For patients with life expectancy <10 years, curative treatment is not recommended; consider observation or palliative approaches 3, 4

The National Comprehensive Cancer Network recommends using PSMA PET/CT as the preferred imaging modality for detecting occult metastatic disease when PSA <10 ng/mL 1
Pelvic imaging should be obtained unless disease is low-volume and low-risk (PSA <1.0, Gleason score <7, PSA doubling time >15 months) 1

The American College of Radiology recommends salvage radiotherapy as the primary treatment for PSA biochemical recurrence after prostatectomy without distant metastases, with a minimum dose of 64-66 Gy to the prostatic bed 1
Salvage radiotherapy should be initiated at the earliest sign of PSA recurrence and at the lowest possible PSA level (preferably <0.5 ng/mL) to maximize disease control and reduce prostate cancer-specific mortality 1
Patients receiving radiotherapy at PSA <0.5 ng/mL achieve 6-year biochemical progression-free survival of 48%, compared to 18% when PSA is >1.5 ng/mL 1

The National Comprehensive Cancer Network recommends that androgen deprivation therapy (ADT) should NOT be routinely initiated for biochemical relapse alone, as retrospective series show no survival benefit despite delayed time to clinical metastases 1
ADT should be considered selectively for high-risk features, such as PSA doubling time <3 months, symptomatic local disease progression, or proven metastatic disease 1
If ADT is initiated, intermittent rather than continuous therapy should be used, based on Level I evidence showing non-inferior overall survival with superior quality of life 1

The National Comprehensive Cancer Network recommends that men older than 70 years are more likely to have higher grade and stage disease and worse survival compared to younger counterparts 6
Screening and aggressive treatment beyond age 75 should be highly selective, as many elderly men harbor cancer unlikely to affect life expectancy 7, 6
For men aged 75+ with PSA <3.0 ng/mL, they are unlikely to die from prostate cancer and may safely discontinue aggressive surveillance 6

The American Urological Association recommends monitoring PSA every 3-6 months initially after salvage radiotherapy, and continuing annual PSA monitoring indefinitely 2
PSA doubling time <6 months is associated with higher risk and need for intervention 2